From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy (Q64084791)

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Extrapancreatic Glucagons

1 reference

12 December 2020

Identification and processing of proglucagon in pancreatic islets

1 reference

12 December 2020

Effect of secretin on basal- and glucose-stimulated insulin secretion in man.

1 reference

12 December 2020

Purification and characterization of a protein from porcine gut with glucagon-like immunoreactivity

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

The new enzymology of precursor processing endoproteases

1 reference

12 December 2020

Entero-insular axis and diabetes mellitus

1 reference

12 December 2020

Glucagon-like immunoreactivity in hypothalamic neurons of the rat.

1 reference

12 December 2020

Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain

1 reference

12 December 2020

Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8

1 reference

12 December 2020

Complete sequences of glucagon-like peptide-1 from human and pig small intestine

1 reference

12 December 2020

Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

1 reference

12 December 2020

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

12 December 2020

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

12 December 2020

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

12 December 2020

Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

12 December 2020

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

1 reference

12 December 2020

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

12 December 2020

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

12 December 2020

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

1 reference

12 December 2020

Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).

1 reference

12 December 2020

New developments in the incretin concept

1 reference

12 December 2020

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

1 reference

12 December 2020

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

12 December 2020

Radioimmunological determination of pancreatic and gut glucagon in plasma

1 reference

12 December 2020

Structural evidence for glucagon producing cells in the intestinal mucosa of the rat

1 reference

12 December 2020

Control of Pancreatic Glucagon Secretion by Glucose

1 reference

12 December 2020

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

1 reference

12 December 2020

Gastric inhibitory polypeptide

1 reference

12 December 2020

Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours

1 reference

12 December 2020

Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption

1 reference

12 December 2020

Hamster preproglucagon contains the sequence of glucagon and two related peptides

1 reference

12 December 2020

Exon duplication and divergence in the human preproglucagon gene

1 reference

12 December 2020

Evidence that glicentin contains the entire sequence of glucagon

1 reference

12 December 2020

The primary structure of porcine glicentin (proglucagon)

1 reference

12 December 2020

Glucagon precursors identified by immunoprecipitation of products of cell-free translation of messenger RNA.

1 reference

12 December 2020

Relationship of glicentin to proglucagon and glucagon in the porcine pancreas

1 reference

12 December 2020

Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man

1 reference

12 December 2020

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

1 reference

12 December 2020

Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Isolation of the peptide

1 reference

12 December 2020

Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide

1 reference

12 December 2020

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin

1 reference

12 December 2020

Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man

1 reference

12 December 2020

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide

1 reference

12 December 2020

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

1 reference

12 December 2020

Ileal release of glucagon-like peptide-1 (GLP-1)

1 reference

12 December 2020

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Proglucagon processing in porcine and human pancreas

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

1 reference

12 December 2020

Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

12 December 2020

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

12 December 2020

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites

1 reference

12 December 2020

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1 reference

12 December 2020

Expression of the glucagon-like peptide-1 receptor gene in rat brain.

1 reference

12 December 2020

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

1 reference

12 December 2020

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1 reference

12 December 2020

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats

1 reference

12 December 2020

Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.

1 reference

12 December 2020

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

1 reference

12 December 2020

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

1 reference

12 December 2020

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

12 December 2020

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

12 December 2020

Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow.

1 reference

12 December 2020

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

12 December 2020

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

1 reference

12 December 2020

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

12 December 2020

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

12 December 2020

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

12 December 2020

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

12 December 2020

cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.

1 reference

12 December 2020

Purification and crystallization of hyperglycemic glycogenolytic factor (HGF)

1 reference

12 December 2020

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

1 reference

12 December 2020

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

1 reference

12 December 2020

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

1 reference

12 December 2020

Depression of insulin release by anti-GIP serum after oral glucose in rats

1 reference

12 December 2020

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

1 reference

12 December 2020

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

12 December 2020

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

1 reference

12 December 2020

Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas.

1 reference

12 December 2020

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

1 reference

12 December 2020

Impaired regulation of the incretin effect in patients with type 2 diabetes.

1 reference

12 December 2020

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

1 reference

12 December 2020

Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans

1 reference

12 December 2020

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

1 reference

12 December 2020

The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.

1 reference

12 December 2020

Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.

1 reference

12 December 2020

A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes

1 reference

12 December 2020

Incretin effect after oral amino acid ingestion in humans.

1 reference

12 December 2020

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

1 reference

12 December 2020

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

12 December 2020

A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

1 reference

12 December 2020

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

Age-dependent human β cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling

1 reference

12 December 2020

Discovery, characterization, and clinical development of the glucagon-like peptides

1 reference

12 December 2020

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.

1 reference

12 December 2020

Oxyntomodulin: Actions and role in diabetes

1 reference

12 December 2020

The safety of gliptins : updated data in 2018.

1 reference

12 December 2020

The Origin and Understanding of the Incretin Concept

1 reference

12 December 2020

Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for t

1 reference

12 December 2020

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

1 reference

12 December 2020

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

1 reference

12 December 2020